IL272768A - Compounds and methods for modulating adenosine a2b receptor and adenosine a2a receptor - Google Patents

Compounds and methods for modulating adenosine a2b receptor and adenosine a2a receptor

Info

Publication number
IL272768A
IL272768A IL272768A IL27276820A IL272768A IL 272768 A IL272768 A IL 272768A IL 272768 A IL272768 A IL 272768A IL 27276820 A IL27276820 A IL 27276820A IL 272768 A IL272768 A IL 272768A
Authority
IL
Israel
Prior art keywords
receptor
adenosine
compounds
methods
modulating
Prior art date
Application number
IL272768A
Other languages
Hebrew (he)
Inventor
Erik Verner
Zhihong Li
Lubov Konstantinovna Filonova
Erin Kathleen Bradley
Original Assignee
Corvus Pharmaceuticals Inc
Erik Verner
Zhihong Li
Lubov Konstantinovna Filonova
Erin Kathleen Bradley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corvus Pharmaceuticals Inc, Erik Verner, Zhihong Li, Lubov Konstantinovna Filonova, Erin Kathleen Bradley filed Critical Corvus Pharmaceuticals Inc
Publication of IL272768A publication Critical patent/IL272768A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL272768A 2017-08-31 2020-02-19 Compounds and methods for modulating adenosine a2b receptor and adenosine a2a receptor IL272768A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762553006P 2017-08-31 2017-08-31
US201862654181P 2018-04-06 2018-04-06
PCT/US2018/049206 WO2019046784A1 (en) 2017-08-31 2018-08-31 Compounds and methods for modulating adenosine a2b receptor and adenosine a2a receptor

Publications (1)

Publication Number Publication Date
IL272768A true IL272768A (en) 2020-04-30

Family

ID=65526122

Family Applications (1)

Application Number Title Priority Date Filing Date
IL272768A IL272768A (en) 2017-08-31 2020-02-19 Compounds and methods for modulating adenosine a2b receptor and adenosine a2a receptor

Country Status (10)

Country Link
US (1) US11254686B1 (en)
EP (1) EP3675856A4 (en)
JP (1) JP2020532541A (en)
KR (1) KR20200061346A (en)
CN (1) CN111629728A (en)
AU (1) AU2018325451A1 (en)
CA (1) CA3073915A1 (en)
IL (1) IL272768A (en)
WO (1) WO2019046784A1 (en)
ZA (1) ZA202001268B (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915437D0 (en) 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
GB0100620D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
CA2646333C (en) * 2006-03-17 2014-06-17 Cv Therapeutics, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists
GB0718434D0 (en) 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
GB0718432D0 (en) * 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
US20100093714A1 (en) 2008-10-13 2010-04-15 Devraj Chakravarty AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
JP5827998B2 (en) * 2010-09-13 2015-12-02 アドヴィナス・セラピューティックス・リミテッド Purine compounds as prodrugs of A2B adenosine receptor antagonists, application of these methods and agents
JP6779204B2 (en) 2014-11-18 2020-11-04 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Aminopyrazine compound with A2A antagonist properties
US20200079793A1 (en) 2018-08-31 2020-03-12 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating adenosine a2b receptor and adenosine a2a receptor

Also Published As

Publication number Publication date
EP3675856A1 (en) 2020-07-08
CA3073915A1 (en) 2019-03-07
ZA202001268B (en) 2022-07-27
EP3675856A4 (en) 2021-04-14
US11254686B1 (en) 2022-02-22
JP2020532541A (en) 2020-11-12
CN111629728A (en) 2020-09-04
WO2019046784A1 (en) 2019-03-07
KR20200061346A (en) 2020-06-02
AU2018325451A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
SG11201912267SA (en) Nicotinamide riboside derivatives and their uses
HK1245800A1 (en) Substituted nucleosides, nucleotides and analogs thereof
HK1245279A1 (en) Substituted nucleosides, nucleotides and analogs thereof
HUE060123T2 (en) Novel nucleoside triphosphate transporter and uses thereof
IL249628A0 (en) Substituted nucleosides, nucleotides and analogs thereof
IL249627A0 (en) Substituted nucleosides, nucleotides and analogs thereof
EP3372037C0 (en) Methods and apparatus for multiple user uplink
IL253656A0 (en) Substituted mono- and polyazanaphthalene derivatives and their use
HK1216582A2 (en) Climbing hold and rock climbing system for use in rock climbing
HK1217201A1 (en) Method for preparing nucleoside analogue and intermediate thereof
EP3368663A4 (en) Virus-free cell lines and methods for obtaining same
HK1246165A1 (en) Agent for enhancing atp in cells
IL266111A (en) Methods for promoting t cells response
HK1251226A1 (en) Pyridine and pyrimidine derivatives
IL252118A0 (en) Analytical methods and arrays for use in the same
SG10201602193WA (en) Systems and methods for mass calibration
IL271737A (en) Isotretinoin oral-mucosal formulations and methods for using same
EP3556764A4 (en) Nucleoside derivative and use therefor
ZA201904333B (en) Adenosine a3 receptor modulators
SG11202001495VA (en) Spirothietane nucleosides
IL263852B (en) Oligonucleotides comprising modified nucleosides
ZA202001268B (en) Compounds and methods for modulating adenosine a2b receptor and adenosine a2a receptor
IL273274A (en) Modified nucleoside phosphoramidites
HK1256263A1 (en) Methods and means for dysplasia analysis
PT3529262T (en) Methods for promoting t cells response